Skip to main content

View full-text article in PMC

. 2011 Dec 29;29(2):195–201. doi: 10.1007/s10815-011-9693-7

Table 2.

IRS-1 Gly972Arg polymorphism

	Control group			PCOS group
Variable	Control Gly/Gly mean ± SD	Control Gly/Arg mean ± SD	Pvalue^a	PCOS Gly/Gly (44) mean ± SD	PCOS X/Arg mean ± SD	Pvalue^a
Age	29.8 ± 6.5	28.7 ± 5.8	.778^a	26.4 ± 5.1	27.7 ± 7.6	.787^a
BMI	26.5 ± 4.1	23.5 ± 2.6	.121^a	27.4 ± 5.2	28.2 ± 8.0	.840^a
FBS	87.2 ± 9.0	82.5 ± 15.1	.728^a	87.9 ± 11.0	89.2 ± 8.6	.986^a
2hpp BS	91.9 ± 11.9	107.0 ± 14.1	.037^a	98.9 ± 15.6	92.0 ± 5.0	.290^a
Fasting insulin	12.7 ± 14.5	13.0 ± 3.5	.359^a	18.6 ± 26.9	7.1 ± 5.1	.058^a
HOMA1-IR	2.7 ± 3.2	2.7 ± 1.0	.455^a	4.0 ± 5.5	1.5 ± 1.1	.076^a
Family history	Positive	Negative	Pvalue	Positive	Negative	Pvalue
(Polymorphism frequency within group)%^b	(0/1) 0	(4/47) 7.8	.77	(0/13) 0	(4/35) 11.4	.20
Hirsutism	Positive	Negative	Pvalue	Positive	Negative	Pvalue
(Polymorphism frequency within group)%	(0/6) 0	(4/48) 8.7	.45	(3/12) 3.8	(1/26) 13.6	.22
Insulin resistance	Positive	Negative	Pvalue	Positive	Negative	Pvalue
(Polymorphism frequency within group)%	(1/13) 7.7	(3/39) 7.7	1.00	(0/13) 0	(4/35) 11.4	.20
Overweight and obesity	Positive	Negative	Pvalue	Positive	Negative	Pvalue
(Polymorphism frequency within group)%	(1/31) 3.2	(3/21) 14.3	.14	(3/34) 8.8	(1/14) 7.1	.84

^aTested with Mann–Whitney, p ≤ 0.05

^bThe differences between total number of patients within groups are due to improper documentation